View Filing Data

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2013	Jul. 31, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	AP PHARMA INC /DE/
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		306,969,219
Amendment Flag	false
Entity Central Index Key	0000818033
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2

Condensed Balance Sheet (Unaudited current period) - USD ($) $ in Thousands	Jun. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 34,849	$ 53,506
Prepaid expenses and other current assets	360	584
Total current assets	35,209	54,090
Property and equipment, net	2,733	1,752
Other long-term assets	148	130
Total assets	38,090	55,972
Current liabilities:
Accounts payable	5,350	1,912
Accrued expenses	3,488	1,750
Convertible notes payable to related parties, net of discount	754	492
Total current liabilities	9,592	4,154
Stockholders' equity:
Common stock	3,060	3,024
Additional paid-in capital	237,392	232,381
Accumulated deficit	(211,954)	(183,587)
Total stockholders' equity	28,498	51,818
Total liabilities and stockholders' equity	$ 38,090	$ 55,972

Condensed Statement of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Operating expenses:
Research and development	$ 10,531	$ 3,067	$ 17,303	$ 6,396
General and administrative	4,678	1,313	10,659	2,753
Total operating expenses	15,209	4,380	27,962	9,149
Operating loss	(15,209)	(4,380)	(27,962)	(9,149)
Interest expense, net	(204)	(146)	(405)	(207)
Loss from continuing operations	(15,413)	(4,526)	(28,367)	(9,356)
Loss from discontinued operations		(43)		(134)
Net loss	$ (15,413)	$ (4,569)	$ (28,367)	$ (9,490)
Basic and diluted net loss per share:
Loss from continuing operations (in Dollars per share)	$ (0.05)	$ (0.02)	$ (0.09)	$ (0.05)
Net loss (in Dollars per share)	$ (0.05)	$ (0.02)	$ (0.09)	$ (0.05)
Shares used to compute basic and diluted net loss per share (in Shares)	305,690	200,112	305,384	200,079

Condensed Statement of Cash Flows (Unaudited) - USD ($)	6 Months Ended
Condensed Statement of Cash Flows (Unaudited) - USD ($)	Jun. 30, 2013	Jun. 30, 2012
Cash flows from operating activities:
Net loss	$ (28,367,000)	$ (9,490,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss from discontinued operations		134,000
Depreciation and amortization	149,000	94,000
Stock-based compensation	4,238,000	1,793,000
Amortization of debt discount	261,000	136,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	206,000	(291,000)
Accounts payable	2,849,000	(74,000)
Accrued expenses	1,882,000	(380,000)
Net cash used in operating activities	(18,782,000)	(8,078,000)
Cash flows from investing activities:
Purchases of property and equipment	(541,000)	(467,000)
Net cash used in investing activities	(541,000)	(467,000)
Cash flows from financing activities:
Proceeds from convertible note financing		3,000,000
Proceeds from warrant exercise	600,000
Proceeds from stock option exercise	41,000
Proceeds from the issuance of shares under the Employee Stock Purchase Plan	25,000	13,000
Net cash provided by financing activities	666,000	3,013,000
Net decrease in cash and cash equivalents	(18,657,000)	(5,532,000)
Cash and cash equivalents, beginning of period	53,506,000	17,974,000
Cash and cash equivalents, end of period	$ 34,849,000	$ 12,442,000

Note 1 - Business and Basis of Presentation

6 Months Ended

Jun. 30, 2013

Disclosure Text Block [Abstract]

Basis of Presentation and Significant Accounting Policies [Text Block]

(1) BUSINESS AND BASIS OF PRESENTATION

A.P. Pharma, Inc. (the “Company,” “we,” “us” and “our”) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.

The Company’s lead product candidate, APF530, is being developed for the prevention of both acute chemotherapy-induced nausea and vomiting (CINV) for patients undergoing both moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuations of treatment. There is only one injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical need. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company’s proprietary Biochonomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. This five-day range is designed to cover the delayed phase of CINV. Granisetron was selected for APF530 because it is widely prescribed by physicians based on a well-established record of safety and efficacy.

In May 2009, we filed the original New Drug Application (NDA) seeking approval for APF530 with the U.S. Food and Drug Administration (FDA). The FDA issued a Complete Response Letter for the APF530 NDA in March 2010. In September 2012, we resubmitted the NDA seeking approval for APF530 with the FDA. On March 28, 2013, we announced that the FDA had issued a Complete Response Letter, which identifies several issues that preclude approval of the APF530 NDA in its current form. We believe the issues that remain are addressable, and we will work expeditiously to resubmit the APF530 NDA in the first quarter of 2014.

We own the worldwide rights to APF530 and are in the early stages of building the commercial infrastructure necessary to commercialize APF530 in the U.S. on our own.

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. All adjustments (all of which are of a normal recurring nature) considered necessary for a fair presentation have been included. We have evaluated subsequent events through the date that these financial statements were issued. Operating results for the three and six months ended June 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013 or for any other period. The condensed balance sheet as of December 31, 2012 has been derived from the audited financial statements as of that date, but it does not include all of the information and notes required by U.S. GAAP. These unaudited condensed financial statements and the notes thereto should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2012, which was filed with the Securities and Exchange Commission (SEC) on March 1, 2013 (2012 10-K).

Liquidity

We have incurred significant operating losses and negative cash flows from operations and have an accumulated deficit of $212.0 million as of June 30, 2013. During 2011 and 2012, we entered into three financing agreements, which provided us capital to fund operations. In April 2011, we entered into definitive agreements for a convertible note financing of up to $4.5 million. We received approximately $1.3 million, net of issuance costs, from the initial closing and an additional $3.0 million through the issuance of additional convertible notes in May 2012 as a result of the purchasers who participated in the April 2011 convertible note financing fully exercising their rights to purchase additional convertible notes (see Note 8). In June 2011, we entered into definitive agreements for a private placement of units, which were comprised of common stock and warrants (see Note 9). The unit financing, which closed in July 2011, provided the Company with approximately $22.8 million of proceeds, net of issuance costs. In July 2012, the Company closed a common stock financing whereby the Company received approximately $50.5 million of proceeds, net of issuance costs (see Note 9). As of June 30, 2013, we had cash and cash equivalents of $34.8 million. The Company believes that its current working capital is sufficient to fund its operations into 2014.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. We evaluate our critical accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. Our critical accounting policies and estimates are discussed in our 2012 10-K.

Recent Accounting Pronouncements

There have been no recent accounting pronouncements or changes in accounting pronouncements during the six months ended June 30, 2013, as compared to the recent accounting pronouncements described in our 2012 10-K, that we believe are of significance, or potential significance, to us.

Note 3 - Fair Value Measurements

6 Months Ended

Jun. 30, 2013

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

(3) FAIR VALUE MEASUREMENTS

The three-tier fair value hierarchy utilized prioritizes the inputs used in measuring fair value as follows: Level 1) observable inputs such as quoted prices in active markets; Level 2) inputs other than the quoted prices in active markets that are observable either directly or indirectly; and Level 3) unobservable inputs in which there is little or no market data, which require us to develop our own assumptions. The hierarchy requires us to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. We measured our available-for-sale securities at fair value on a recurring basis. We used quoted prices in active markets (Level l) to measure the fair value of our cash equivalents on our Condensed Balance Sheets as of December 31, 2012. Cash equivalents consisted of highly rated money market funds with maturities of ninety days or less. Due to the high ratings and short-term nature of these funds, we consider the inputs used to value all cash equivalents as Level 1 inputs.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 5 - Stock-Based Compensation

6 Months Ended

Jun. 30, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

(5) STOCK-BASED COMPENSATION

The following table summarizes the stock-based compensation expense for all awards (in thousands, except per share amounts):

	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012

Operating expenses:
Research and development	$	402	$	360	$	544	$	664
General and administrative		2,001		655		3,694		1,129
Total stock-based compensation expense	$	2,403	$	1,015	$	4,238	$	1,793

Impact on basic and diluted net loss per common share	$	0.01	$	0.01	$	0.01	$	0.01

The following table summarizes stock option activity for the six months ended June 30, 2013:

	Shares (in thousands)			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (Years)

Outstanding at January 1, 2013		86,478		$	0.42		8.2
Granted		69,732		$	0.40
Exercised		(172	)	$	0.23
Expired and forfeited		(21,097	)	$	0.56
Outstanding at June 30, 2013		134,941		$	0.39		8.9

Employee Stock Purchase Plan

We adopted an Employee Stock Purchase Plan (Purchase Plan) in 1997. Qualified employees may elect to have a certain percentage of their salary withheld to purchase shares of our common stock under the Purchase Plan. In June 2011, our stockholders authorized an increase in the number of shares reserved for issuance under the Purchase Plan by 500,000, for a total of 1,000,000 shares reserved at June 30, 2013. The purchase price per share is equal to 85% of the fair market value of the stock on specified dates. Sales under the Purchase Plan during the six months ended June 30, 2013 and 2012 consisted of 80,027 and 58,571 shares at an average price of $0.31 and $0.21, respectively. Shares available for future purchase under the Purchase Plan were 365,674 at June 30, 2013.

Note 7 - Discontinued Operations

6 Months Ended

Jun. 30, 2013

Discontinued Operations and Disposal Groups [Abstract]

Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]

(7) DISCONTINUED OPERATIONS

Cosmeceutical and Toiletry Business

On July 25, 2000, we completed the sale of certain technology rights for our cosmeceutical and toiletry business to RP Scherer Corporation (RP Scherer), a subsidiary of Cardinal Health, Inc. Under the terms of the agreement with RP Scherer, we guaranteed a minimum gross profit percentage on RP Scherer's combined sales of products to Ortho Dermatologics (Ortho) and Dermik Laboratories, Inc. (Dermik) (Gross Profit Guaranty). In July 2011, Valeant Pharmaceuticals announced it was acquiring both Ortho and Dermik. The guaranty period initially commenced on July 1, 2000 and was to end on the earlier of July 1, 2010 or the end of two consecutive guaranty periods where the combined gross profit on sales to Ortho and Dermik equals or exceeds the guaranteed gross profit (Two Period Test). The Gross Profit Guaranty expense totaled $944,000 for the first seven guaranty years and in those years profits did not meet the Two Period Test. Effective March 2007, in conjunction with a sale of assets by RP Scherer’s successor company to an Amcol International subsidiary (Amcol), a new agreement was signed between us and Amcol to provide continuity of product supply to Ortho and Dermik. This new agreement potentially extended the Gross Profit Guaranty period an additional two years to July 1, 2013, unless it was terminated earlier with the Two Period Test. In February 2013, an arbitrator ruled that no additional amounts were owed under the gross profit guaranty and that the term of the gross profit guaranty has ended. We had previously recorded a liability of the $1.1 million related to the amount that Amcol asserted was due under the Gross Profit Guaranty. This event qualified as an adjusting event under ASC 855, Subsequent Event, and in light of the arbitrator’s decision in February 2013, which was final and binding, we reversed this accrual as of December 31, 2012.

The cosmeceutical and toiletry business is reported as discontinued operations for all periods presented in our accompanying Condensed Statements of Operations.

Loss from discontinued operations primarily represents the loss attributable to changes in estimates of our cosmeceutical and toiletry business that was sold to RP Scherer on July 25, 2000, as follows (in thousands):

	Three Months Ended June 30,					Six Months Ended June 30,
	2013		2012			2013		2012
Cosmeceutical and Toiletry Business
Change in estimates for gross profit guarantees	$	-	$	(43	)	$	-	$	(134	)

There was no material basic and diluted loss per common share resulting from discontinued operations for the three and six months ended June 30, 2013 and 2012.

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

+ Details

Note 8 - Convertible Notes to Related Parties

6 Months Ended

Jun. 30, 2013

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

(8) CONVERTIBLE NOTES TO RELATED PARTIES

In April 2011, we entered into a Securities Purchase Agreement (Purchase Agreement) with certain institutional investors (Purchasers), including a fund affiliated with Kevin C. Tang, who is the Chairman of our Board of Directors, for a private placement of up to $4.5 million in Senior Secured Convertible Notes due 2021 (Notes). The Purchase Agreement provided for the Purchasers to purchase $1.5 million aggregate principal amount of Notes at the initial closing. Pursuant to the Purchase Agreement, the Purchasers had the option to purchase an additional $3.0 million aggregate principal amount of Notes at any time until May 2, 2013 (Purchase Option). The Notes are convertible into shares of the Company’s common stock at a rate of 25,000 shares for every $1,000 of principal and accrued interest due under the Notes (Conversion Shares).

The cash received from the initial closing of the Note financing, which resulted in the issuance of $1.5 million aggregate principal amount of Notes, was approximately $1.3 million, net of issuance costs. In May 2012, the Purchasers exercised their Purchase Option in full, and we received $3.0 million of cash through the issuance of the remaining $3.0 million aggregate principal amount of Notes. As a result of the exercise of the Purchase Option, the Purchasers have purchased the full amount of Notes that the Company was obligated to sell under the Purchase Agreement.

The Notes are secured by substantially all of the assets of the Company, including placing our bank accounts under a control agreement. The Notes initially bore interest at 20% per annum, payable quarterly in cash or in additional principal amount of Notes at the election of the Purchasers. In June 2011, the Notes were amended to reduce the interest rate to 6% per annum effective July 1, 2011. The Notes mature on May 2, 2021; however, the holders of the Notes may require prepayment of the Notes at any time beginning on or after May 2, 2012, at each holder's option.

There is no right to convert the Notes to the extent that, after giving effect to such conversion, the holder would beneficially own in excess of 9.99% of the Company's outstanding common stock. Each holder of the Notes can increase or decrease this beneficial ownership conversion limit by written notice to the Company, which will not be effective until 61 days after delivery of the notice.

As of June 30, 2013, the Company was in compliance with all debt-related covenants under the Notes. Upon the occurrence of an event of default under the Notes, the holders of the Notes have the right to require the Company to redeem all or a portion of their Notes.

Pursuant to the Purchase Agreement, the Company filed a registration statement on Form S-1, registering for resale 69.6 million shares underlying the Notes. The registration statement was declared effective on July 29, 2011. The Purchasers have agreed to waive their right to require the Company to maintain the effectiveness of the registration statement and to register the additional shares underlying the Notes until they provide notice otherwise.

The Notes contain an embedded conversion feature that was in-the-money on both issuance dates. Based on an effective fixed conversion rate of 25,000 shares for every $1,000 of principal and accrued interest due under the Notes, the total conversion benefit at issuance exceeded the loan proceeds. Therefore, a full debt discount was recorded in an amount equal to the face value of the Notes on the issuance dates, and the Company began amortizing the resultant debt discount over the respective 10-year or remaining term of the Notes. During the three months ended June 30, 2013, accrued interest of approximately $72,000 was paid-in-kind and rolled into the principal balance of the Notes, which resulted in an additional full debt discount for the respective periods. For the three and six months ended June 30, 2013, interest expense relating to the stated rate of the Notes was approximately $73,000 and $145,000, respectively. Interest expense relating to the amortization of debt discount for the three and six months ended June 30, 2013 was approximately $132,000 and $261,000, respectively.

As of June 30, 2013, the carrying value of the Notes was approximately $754,000, which is comprised of the $4,885,000 principal amount of the Notes outstanding, less debt discount of $4,131,000. If the $4.9 million principal amount of Notes is converted, the Company would issue 122.1 million shares of its common stock. Accrued interest on the principal balance was $73,000 at June 30, 2013.

Note 9 - Stockholders' Equity

6 Months Ended

Jun. 30, 2013

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

(9) STOCKHOLDERS' EQUITY

Amendments to Articles of Incorporation

In June 2011, we amended our certificate of incorporation to increase the number of shares of authorized common stock to 1,500,000,000, par value $0.01 per share. Prior to the amendment, the number of shares of authorized common stock was 100,000,000, par value $0.01 per share. The certificate of amendment was approved by a majority of our stockholders on June 29, 2011.

Stock Plans

At our annual meeting of stockholders in June 2011, our stockholders approved an amendment to our 2007 Equity Incentive Plan to increase the maximum number of shares of common stock available for grant by 90,000,000 shares of common stock, resulting in an aggregate of 95,000,000 shares of common stock authorized for issuance pursuant to awards granted under our 2007 Equity Incentive Plan. The stockholders also approved an amendment to our 1997 Employee Stock Purchase Plan to increase the number of shares of common stock reserved for issuance under the plan by 500,000, for a total of 1,000,000 shares reserved as of June 30, 2013.

2011 Private Placement

In June 2011, we entered into a Securities Purchase Agreement with certain purchasers (Securities Purchase Agreement), pursuant to which we agreed to sell 160,000,006 shares of our common stock (Shares) and warrants to purchase 80,000,005 shares of our common stock (Warrants) with an exercise price of $0.18 per share (2011 Private Placement), for an aggregate price of $24.0 million. The 2011 Private Placement closed on July 1, 2011. For each share purchased, the investors received one Warrant to purchase 0.5 shares of common stock (together with a Share, a Unit), at a purchase price of $0.15 per Unit. The Warrants were immediately exercisable and expire on the fifth anniversary of the closing date of July 1, 2011. The Warrants may be exercised for cash only or, if a registration statement is not then effective and available for the resale of the shares of common stock issuable upon exercise of the Warrants, by surrender of such Warrant, or a portion of such Warrant, by way of cashless exercise. There is no right to exercise the Warrants to the extent that after giving effect to such exercise the holder would beneficially own in excess of 9.99% of our outstanding shares of common stock or such other limit as may be designated by any particular purchaser. Each holder of the Warrants can amend or waive the foregoing limitation by written notice to the Company, with such waiver taking effect only upon the expiration of a 61-day notice period.

Under the terms of the Securities Purchase Agreement, on July 29, 2011, the Company filed a registration statement with the SEC to register for resale the Shares and the shares of common stock issuable upon the exercise of the Warrants (the Warrant Shares, and collectively with the Shares, the Registrable Securities). The registration statement was declared effective on August 4, 2011. The Company is obligated to maintain the effectiveness of the registration statement with respect to an investor’s Registrable Securities until the investor is able to sell the Registrable Securities without limitation or restriction under Rule 144. There is currently only one investor who is an affiliate of the Company and is therefore not able to sell the Registrable Securities without limitation under Rule 144, and that investor has agreed to waive their right to require the Company to maintain the effectiveness of the registration statement until they provide notice otherwise. If the Company fails to keep the registration statement continuously effective for a designated time (with limited exceptions) during the period the Company is obligated to maintain the registration statement, the Company may be obligated to pay to the holders of the Registrable Securities liquidated damages in an amount equal to 1.0% per month of such holder's pro rata interest in the total purchase price of the Private Placement, capped at a total penalty of 6.0%.

The Company received total proceeds of $22.8 million from the 2011 Private Placement, which was net of issuance costs of approximately $1.2 million. During the six months ended June 30, 2013, the Company received $0.6 million for an exercise of a Warrant.

2012 Private Placement

In July 2012, the Company entered into a securities purchase agreement with certain purchasers, pursuant to which the Company agreed to sell 102,000,000 shares of its common stock (2012 Shares) at a purchase price of $0.525 per share of common stock, for an aggregate price of approximately $53.6 million (2012 Private Placement). The 2012 Private Placement closed on July 30, 2012.

In connection with entering into the securities purchase agreement, the Company also entered into a registration rights agreement. On August 24, 2012, the Company filed a registration statement with the SEC to register the 2012 Shares for resale. The registration statement was declared effective on September 6, 2012. If the Company fails to keep the registration statements continuously effective for a designated time (with limited exceptions), the Company may be obligated to pay to each holder of the 2012 Shares an amount equal to 1.5% per month of the aggregate purchase price of the unregistered 2012 Shares held by such holder, capped at a total penalty of 9.0%.

The Company received total proceeds of $50.5 million from the 2012 Private Placement, which was net of issuance costs of approximately $3.1 million.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Accounting Policies, by Policy (Policies)	6 Months Ended
Accounting Policies, by Policy (Policies)	Jun. 30, 2013
Accounting Policies [Abstract]
Nature of Operations [Text Block]	A.P. Pharma, Inc. (the “Company,” “we,” “us” and “our”) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Company’s lead product candidate, APF530, is being developed for the prevention of both acute chemotherapy-induced nausea and vomiting (CINV) for patients undergoing both moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuations of treatment. There is only one injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical need. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company’s proprietary Biochonomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. This five-day range is designed to cover the delayed phase of CINV. Granisetron was selected for APF530 because it is widely prescribed by physicians based on a well-established record of safety and efficacy. In May 2009, we filed the original New Drug Application (NDA) seeking approval for APF530 with the U.S. Food and Drug Administration (FDA). The FDA issued a Complete Response Letter for the APF530 NDA in March 2010. In September 2012, we resubmitted the NDA seeking approval for APF530 with the FDA. On March 28, 2013, we announced that the FDA had issued a Complete Response Letter, which identifies several issues that preclude approval of the APF530 NDA in its current form. We believe the issues that remain are addressable, and we will work expeditiously to resubmit the APF530 NDA in the first quarter of 2014. We own the worldwide rights to APF530 and are in the early stages of building the commercial infrastructure necessary to commercialize APF530 in the U.S. on our own.
Basis of Accounting, Policy [Policy Text Block]	The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. All adjustments (all of which are of a normal recurring nature) considered necessary for a fair presentation have been included. We have evaluated subsequent events through the date that these financial statements were issued. Operating results for the three and six months ended June 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013 or for any other period. The condensed balance sheet as of December 31, 2012 has been derived from the audited financial statements as of that date, but it does not include all of the information and notes required by U.S. GAAP. These unaudited condensed financial statements and the notes thereto should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2012, which was filed with the Securities and Exchange Commission (SEC) on March 1, 2013 (2012 10-K).
Liquidity Disclosure [Policy Text Block]	Liquidity We have incurred significant operating losses and negative cash flows from operations and have an accumulated deficit of $212.0 million as of June 30, 2013. During 2011 and 2012, we entered into three financing agreements, which provided us capital to fund operations. In April 2011, we entered into definitive agreements for a convertible note financing of up to $4.5 million. We received approximately $1.3 million, net of issuance costs, from the initial closing and an additional $3.0 million through the issuance of additional convertible notes in May 2012 as a result of the purchasers who participated in the April 2011 convertible note financing fully exercising their rights to purchase additional convertible notes (see Note 8). In June 2011, we entered into definitive agreements for a private placement of units, which were comprised of common stock and warrants (see Note 9). The unit financing, which closed in July 2011, provided the Company with approximately $22.8 million of proceeds, net of issuance costs. In July 2012, the Company closed a common stock financing whereby the Company received approximately $50.5 million of proceeds, net of issuance costs (see Note 9). As of June 30, 2013, we had cash and cash equivalents of $34.8 million. The Company believes that its current working capital is sufficient to fund its operations into 2014.
Significant Accounting Policies [Text Block]	Critical Accounting Policies and Estimates The preparation of financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. We evaluate our critical accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. Our critical accounting policies and estimates are discussed in our 2012 10-K.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements There have been no recent accounting pronouncements or changes in accounting pronouncements during the six months ended June 30, 2013, as compared to the recent accounting pronouncements described in our 2012 10-K, that we believe are of significance, or potential significance, to us.

Note 5 - Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2013

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012

Operating expenses:
Research and development	$	402	$	360	$	544	$	664
General and administrative		2,001		655		3,694		1,129
Total stock-based compensation expense	$	2,403	$	1,015	$	4,238	$	1,793

Impact on basic and diluted net loss per common share	$	0.01	$	0.01	$	0.01	$	0.01

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

	Shares (in thousands)			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (Years)

Outstanding at January 1, 2013		86,478		$	0.42		8.2
Granted		69,732		$	0.40
Exercised		(172	)	$	0.23
Expired and forfeited		(21,097	)	$	0.56
Outstanding at June 30, 2013		134,941		$	0.39		8.9

Note 1 - Business and Basis of Presentation (Details) - USD ($) $ in Thousands	1 Months Ended			6 Months Ended	7 Months Ended
	Jul. 31, 2012	May 31, 2012	Apr. 30, 2011	Jun. 30, 2012	Jul. 31, 2011	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Net Of Issuance Costs [Member]
Note 1 - Business and Basis of Presentation (Details) [Line Items]
Proceeds from Convertible Debt			$ 1,300
Purchase Option [Member]
Note 1 - Business and Basis of Presentation (Details) [Line Items]
Proceeds from Convertible Debt		$ 3,000
Private Placement [Member]
Note 1 - Business and Basis of Presentation (Details) [Line Items]
Proceeds From Sale Of Units Of Common Stock And Warrants Net (in Dollars)					$ 22,800
Retained Earnings (Accumulated Deficit)						$ (211,954)	$ (183,587)
Convertible Debt Issuable In Connection With Private Placement1			$ 4,500
Proceeds from Convertible Debt				$ 3,000
Proceeds from Issuance of Private Placement (in Dollars)	$ 50,500
Cash and Cash Equivalents, at Carrying Value				$ 12,442		$ 34,849	$ 53,506	$ 17,974

Note 5 - Stock-Based Compensation (Details) - $ / shares	1 Months Ended	6 Months Ended
	Jun. 30, 2011	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Employee Stock Purchase Plan 1997 [Member]
Note 5 - Stock-Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized				500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent		85.00%
Stock Issued During Period, Shares, Employee Stock Purchase Plans		80,027	58,571
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)		$ 0.31	$ 0.21
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		365,674
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	90,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	95,000,000			95,000,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)		$ 0.40

Note 5 - Stock-Based Compensation (Details) - Stock-based Option Details - $ / shares shares in Thousands	6 Months Ended
	Jun. 30, 2013	Dec. 31, 2012
Stock-based Option Details [Abstract]
Shares	134,941	86,478
Weighted Average Exercise Price (in Dollars per share)	$ 0.39	$ 0.42
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	8 years 328 days	8 years 73 days
Granted	69,732
Granted (in Dollars per share)	$ 0.40
Exercised	(172)
Exercised (in Dollars per share)	$ 0.23
Expired and forfeited	(21,097)
Expired and forfeited (in Dollars per share)	$ 0.56

Note 8 - Convertible Notes to Related Parties (Details)		1 Months Ended			3 Months Ended	6 Months Ended
Note 8 - Convertible Notes to Related Parties (Details)	Jul. 29, 2011 shares	May 31, 2012 USD ($)	Jul. 01, 2011	Apr. 30, 2011 USD ($) shares	Jun. 30, 2013 USD ($)	Jun. 30, 2013 USD ($)	Jun. 30, 2012 USD ($)	Dec. 31, 2012 USD ($)
Initial Closing Amount [Member]
Note 8 - Convertible Notes to Related Parties (Details) [Line Items]
Notes Authorized Under Private Placement Initial Closing				$ 1,500,000
Purchase Option [Member]
Note 8 - Convertible Notes to Related Parties (Details) [Line Items]
Purchase Option Under Private Placement				$ 3,000,000
Common Stock [Member]
Note 8 - Convertible Notes to Related Parties (Details) [Line Items]
Debt Instrument Conversion Ratio, Shares (in Shares) \| shares				25,000
Principal Amount [Member]
Note 8 - Convertible Notes to Related Parties (Details) [Line Items]
Debt Instrument, Convertible, Conversion Ratio				1,000
Senior Notes [Member]
Note 8 - Convertible Notes to Related Parties (Details) [Line Items]
Convertible Debt Issuable In Connection With Private Placement1				$ 4,500,000
Proceeds from Debt, Net of Issuance Costs		$ 3,000,000		$ 1,300,000
Debt Instrument, Interest Rate, Stated Percentage			6.00%	20.00%
Debt Instrument, Maturity Date			May 02, 2021
Debt Instrument, Maturity Date Range, Start			May 02, 2012
Beneficial Ownership After Conversion			9.99%
Notice Period Associated with Beneficial Ownership Percentage Limitation, Convertible Notes			61 days
Carrying Value of Notes Outstanding					$ 754,000	$ 754,000
Debt Instrument, Face Amount					4,885,000	4,885,000
Debt Instrument, Unamortized Discount					4,131,000	$ 4,131,000
Debt Instrument, Convertible, Number of Equity Instruments						122,100,000
Payment in Kind (PIK) Note [Member]
Note 8 - Convertible Notes to Related Parties (Details) [Line Items]
Paid-in-Kind Interest					72,000
Convertible Debt Issuable In Connection With Private Placement1				$ 4,500,000
Common Shares Registered For Resale In Connection With Convertible Notes (in Shares) \| shares	69,600,000
Interest Expense, Debt, Excluding Amortization					73,000	$ 145,000
Amortization of Debt Discount (Premium)					132,000	261,000	$ 136,000
Carrying Value of Notes Outstanding					754,000	754,000		$ 492,000
Interest Payable, Current					$ 73,000	$ 73,000

Note 9 - Stockholders' Equity (Details) $ / shares in Units, $ in Thousands	1 Months Ended		2 Months Ended	6 Months Ended		7 Months Ended	12 Months Ended	25 Months Ended
	Jul. 31, 2012 USD ($)	Jun. 30, 2011 $ / item shares	Jul. 31, 2011 USD ($) $ / item shares	Jun. 30, 2013 USD ($) shares	Jun. 30, 2012 USD ($)	Jul. 30, 2012 USD ($) $ / shares shares	Jun. 30, 2013 shares	Jun. 30, 2013 shares	Jun. 29, 2011 $ / shares shares	Jun. 28, 2011 $ / shares shares
Stock Compensation Plan [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Increase in the Number of Shares of Common Stock Reserved for Issuance		500,000
Common Stock, Capital Shares Reserved for Future Issuance				1,000,000			1,000,000	1,000,000
Private Placement 2011 [Member] \| Common Stock [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Sale of Stock, Number of Shares Issued in Transaction		160,000,006
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		80,000,005
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item) \| $ / item		0.18
Private Placement 2011 [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Proceeds from Issuance of Private Placement (in Dollars) \| $			$ 24,000
Effective Rate Of Liquidated Damages								1.00%
Private Placement Capped Penatly								6.00%
Proceeds From Sale Of Units Of Common Stock And Warrants Net (in Dollars) \| $			22,800
Payments of Stock Issuance Costs (in Dollars) \| $			$ 1,200
Private Placement 2012 [Member] \| Common Stock [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues						102,000,000
Share Price (in Dollars per share) \| $ / shares						$ 0.525
Private Placement 2012 [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Proceeds from Issuance of Private Placement (in Dollars) \| $					$ 50,500	$ 53,600
Effective Rate Of Liquidated Damages							1.50%
Private Placement Capped Penatly							9.00%
Payments of Stock Issuance Costs (in Dollars) \| $					$ 3,100
Common Stock, Shares Authorized									1,500,000,000	100,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share) \| $ / shares									$ 0.01	$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		90,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		95,000,000
Proceeds from Issuance of Private Placement (in Dollars) \| $	$ 50,500
Shares Available Per Warrant ExercisedCommonStock			0.5
Exercise Price Arrangement, Warrants To Purchase Shares, Purchase Price Per Unit (in Dollars per Item) \| $ / item			0.15
Limitation On Exercisable Warrants								9.99%
Proceeds from Warrant Exercises (in Dollars) \| $				$ 600

Note 4 - Net Loss Per Share (Details) - Outstanding potentially dilutive options, warrants and convertible notes - shares shares in Thousands	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	134,941	63,662
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	81,044	83,977
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	122,125	115,520

Note 7 - Discontinued Operations (Details) - USD ($)	12 Months Ended	84 Months Ended
Note 7 - Discontinued Operations (Details) - USD ($)	Dec. 31, 2012	Jun. 30, 2007
Discontinued Operations and Disposal Groups [Abstract]
Liabilities for Guarantees on Long-Duration Contracts, Benefits Paid		$ 944,000
Increase (Decrease) in Other Accrued Liabilities	$ 1,100,000

Note 7 - Discontinued Operations (Details) - Loss from discontinued operations - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2012
Cosmeceutical and Toiletry Business
Change in estimates for gross profit guarantees	$ (43)	$ (134)